Evidence map›Paper›PMID 41717789›Full record

Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2026

Adverse symptoms attributed to e-cigarettes over 6 months among participants of a randomized controlled trial testing nicotine free-base e-cigarettes for smoking cessation: secondary analysis of the ESTxENDS trial.

Eva Güttinger, Angela Mosimann, Kali Tal, Anna Schoeni, Isabelle Jacot-Sadowski, Jean-Paul Humair, Susanne Pohle, Anja Frei, Seraina Netzer, Aurélie Berthet and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eva GüttingerInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Angela MosimannInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Kali TalInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Anna SchoeniInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Isabelle Jacot-SadowskiCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Jean-Paul HumairDepartment of Primary Care Medicine, University Hospitals of Geneva, Geneva, Switzerland.
Susanne PohleLung Center, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Anja FreiEpidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-7134-1000
Seraina NetzerInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Aurélie BerthetCenter for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Stéphanie BaggioInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.ORCID 0000-0002-5347-5937
Reto AuerInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Julian JakobInstitute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.ORCID 0000-0001-8429-3231

Funding

Lunge ZürichSwiss Cancer Research KFS4744-02-2019Swiss National Science Foundation IICT_33IC30_173552Swiss Tobacco Prevention Fund 19.017477
6 · The paper itself

Abstract

introductionPeople smoking tobacco cigarettes and switching to e-cigarettes report adverse symptoms attributed to e-cigarettes. We aimed at assessing the proportions and changes over 6 months in self-reported symptoms among participants of a large randomized controlled trial testing e-cigarettes for smoking cessation.

methodWe included participants from the intervention group of the Efficacy, Safety and Toxicology of ENDS (ESTxENDS) randomized controlled trial. They received e-cigarettes, freebase nicotine e-liquids and smoking cessation counseling, phone follow-up at 1-, 2-, 4-, 8-week, and a visit at 6 months after target quit date. A set of predefined adverse symptoms experienced while vaping or smoking were systematically assessed at each contact. We used descriptive statistics and mixed models to report proportion of symptoms over time in exclusive e-cigarette users. We assessed the effect of symptoms on smoking re-initiation and the effect of duration of exclusive e-cigarette use on the resolution of symptoms in marginal structural models.

resultsThe intervention group included 622 participants, with a mean age of 40 (SD: 14) and 53% identified as men. After 1 week, the most commonly reported adverse symptoms among the 405 exclusive e-cigarette users were dry mouth (34%, 95 CI: 29%-39%), mouth/throat irritation (23%, 19%-27%), and cough (25%, 21%-29%). After 6 months, 256 exclusive e-cigarette users reported dry mouth (18%, 14%-23%), mouth/throat irritation (11%, 7%-15%), and cough (12%, 8%-16%). Marginal structural model revealed mouth/throat irritation led to smoking re-initiation, but continuing exclusive e-cigarette use resolved dry mouth in many.

conclusionsAdverse symptoms attributed to e-cigarettes are reported by fewer exclusive e-cigarette users over time. While continued e-cigarette use led to less dry mouth, mouth/throat irritation symptoms seemed to resolve because people experiencing symptoms switched back to smoking tobacco, while continuous exclusive e-cigarette users had less symptoms. IMPLICATIONS: E-cigarette use for smoking cessation can lead to adverse symptoms, such as dry mouth, mouth/throat irritation, and cough. The proportion of these symptoms, especially of dry mouth, was lower in participants still exclusively using e-cigarettes after 6 months than in people after one week of use. These findings are crucial for health care professionals who recommend e-cigarettes for smoking cessation, as they offer practical guidance on how to inform their patients about the possibility of these symptoms when shifting to e-cigarettes.

Indexed as

Electronic Nicotine Delivery SystemsSmoking CessationVapingAdultFemaleHumansMaleMiddle Agede-cigarettesENDSsmokingsmoking cessationsymptomsvaping

Identifiers

PMID41717789
PMCPMC13389526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.